4741 Cisplatin Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin. 15663-27-1 441203 Cl2H4N2Pt White powder. 270°C 2530 mg/L (at 25°C) Following cisplatin doses of 20 to 120 mg/m^2, the concentrations of platinum are highest in liver, prostate, and kidney; somewhat lower in bladder, muscle, testicle, pancreas, and spleen; and lowest in bowel, adrenal, heart, lung, cerebrum, and cerebellum. Platinum is present in tissues for as long as 180 days after the last administration. Alkylating agents work by three different mechanisms: 1) attachment of alkyl groups to DNA bases, resulting in the DNA being fragmented by repair enzymes in their attempts to replace the alkylated bases, preventing DNA synthesis and RNA transcription from the affected DNA, 2) DNA damage via the formation of cross-links (bonds between atoms in the DNA) which prevents DNA from being separated for synthesis or transcription, and 3) the induction of mispairing of the nucleotides leading to mutations. Route of Elimination: The parent compound, cisplatin, is excreted in the urine. Although small amounts of platinum are present in the bile and large intestine after administration of cisplatin, the fecal excretion of platinum appears to be insignificant. Half Life: Cisplatin decays monoexponentially with a half life of 20 to 30 minutes following administrations of 50 or 100 mg/m^2. Cisplatin has a plasma half-life of 30 minutes. The complexes between albumin and the platinum from cisplatin do not dissociate to a significant extent and are slowly eliminated with a minimum half-life of five days or more. 2A, probably carcinogenic to humans. (L135) For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer. EYES: irrigate opened eyes for several minutes under running water. INGESTION: do not induce vomiting. Rinse mouth with water (never give anything by mouth to an unconscious person). Seek immediate medical advice. SKIN: should be treated immediately by rinsing the affected parts in cold running water for at least 15 minutes, followed by thorough washing with soap and water. If necessary, the person should shower and change contaminated clothing and shoes, and then must seek medical attention. INHALATION: supply fresh air. If required provide artificial respiration. 2014-09-11T02:04:56Z 2026-05-14T16:40:57Z http://en.wikipedia.org/wiki/Cisplatin C06911 27899 DB00515 CPT true N[Pt](N)(Cl)Cl Cl2H4N2Pt InChI=1S/2ClH.2H2N.Pt/h2*1H;2*1H2;/q;;2*-1;+4/p-2 DQLATGHUWYMOKM-UHFFFAOYSA-L 298.035 296.939928001 Exogenous Solid -2.19 HMDB14656 CHEMBL2068237 389985 <p>Murray A. Kaplan, Alphonse P. Granatek, &#8220;Process for the preparation of microcrystalline cisplatin.&#8221; U.S. Patent US4322391, issued March 30, 1982.</p> CHEM003644 DTXSID4024983 NS00075433 dichloroplatinumdiamine 52.04 22.8408 10.307110976312632 0 2 2 5.061191028666678 0 0